Enterprise Value

493.9K

Cash

27.32M

Avg Qtr Burn

-5.881M

Short % of Float

1.81%

Insider Ownership

6.53%

Institutional Own.

9.58%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Allocetra (Immunotherapy) Details
Organ failure, Treatment of organ failure associated with Sepsis

Phase 2b

Update

Phase 1/2

Data readout

Allocetra (Immunotherapy) Details
Bone marrow transplantation, Prevention of post-bone marrow transplantations complications

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Tovinontrine (IMR-687) Details
Sickle cell disease, Genetic disorder, Blood disorder

Failed

Discontinued

Allocetra (Immunotherapy) Details
COVID-19, Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued

Tovinontrine (IMR-687) Details
Beta thalessemia, Genetic disorder

Failed

Discontinued